Patient-derived Organoids of Lung Cancer to Test Drug Response

University Hospital, Geneva50 enrolled

Overview

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

The aim of the project is to use a combination of patient-derived organoid models: * To amplify tumour tissue to obtain enough material for genomic and histological analysis * to characterize the lung cancer sub-type * To predict treatment (non)response. The following points will be addressed: 1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour. 2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lung Cancer Organoid

Interventions

Lung tumor resectionPROCEDURE

lung tumor resection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven lung cancer * Age ≥ 18 * Written informed and signed consent * Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour Exclusion Criteria: * Less than 18 years of age * Not able to give informed consent (language, intellectual capacities, etc.) * Not accessible to biopsy and/or surgery sample * Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

Locations (1)

Geneva University Hospitals

Geneva, Switzerland

RECRUITING

Outcomes

Primary Outcomes

Patient-derived organoid establishment

Successful generation of lung cancer organoids (growth of lung tumoral cells). The rate of successful generation of lung cancer organoids could vary with the age of the patient, the histological and molecular subtype of lung cancer

Time frame: 3 years

Patient-derived organoid validation

Proportion of patient-derived organoids that are histologically and genetically identical to the source tumour

Time frame: 5 years

Secondary Outcomes

Drug sensitivity

Drug sensitivity of patient-derived tumour organoids (drug screening and chemotherapy resistance test) Secondary drug effects on patient-derived normal lung organoids

Time frame: 2019 - 2023

Prediction of the response to treatment by the patient-derived organoids

The drug sensitivity was tested on patient-derived tumour organoids, which is compared with clinical response of the chemo- or targeted therapy treatment.

Time frame: 2020 - 2025

Central Contacts

Veronique SERRE-BEINIER, PhD

CONTACT

(0)223795107 veronique.serre-beinier@hcuge.ch

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.